General Information of Drug Therapeutic Target (DTT) (ID: TT06AWU)

DTT Name Phosphodiesterase 3A (PDE3A)
Synonyms cGMP-inhibited 3',5'-cyclic phosphodiesterase A; Phosphodiesterase 3A; Cyclic GMP-inhibited phosphodiesterase A; Cyclic GMP inhibited phosphodiesterase A; CGI-PDE A
Gene Name PDE3A
DTT Type
Successful target
[1]
BioChemical Class
Phosphoric diester hydrolase
UniProt ID
PDE3A_HUMAN
TTD ID
T88975
3D Structure
Download
2D Sequence (FASTA)
Download
3D Structure (PDB)
Download
EC Number
EC 3.1.4.17
Sequence
MAVPGDAARVRDKPVHSGVSQAPTAGRDCHHRADPASPRDSGCRGCWGDLVLQPLRSSRK
LSSALCAGSLSFLLALLVRLVRGEVGCDLEQCKEAAAAEEEEAAPGAEGGVFPGPRGGAP
GGGARLSPWLQPSALLFSLLCAFFWMGLYLLRAGVRLPLAVALLAACCGGEALVQIGLGV
GEDHLLSLPAAGVVLSCLAAATWLVLRLRLGVLMIALTSAVRTVSLISLERFKVAWRPYL
AYLAGVLGILLARYVEQILPQSAEAAPREHLGSQLIAGTKEDIPVFKRRRRSSSVVSAEM
SGCSSKSHRRTSLPCIPREQLMGHSEWDHKRGPRGSQSSGTSITVDIAVMGEAHGLITDL
LADPSLPPNVCTSLRAVSNLLSTQLTFQAIHKPRVNPVTSLSENYTCSDSEESSEKDKLA
IPKRLRRSLPPGLLRRVSSTWTTTTSATGLPTLEPAPVRRDRSTSIKLQEAPSSSPDSWN
NPVMMTLTKSRSFTSSYAISAANHVKAKKQSRPGALAKISPLSSPCSSPLQGTPASSLVS
KISAVQFPESADTTAKQSLGSHRALTYTQSAPDLSPQILTPPVICSSCGRPYSQGNPADE
PLERSGVATRTPSRTDDTAQVTSDYETNNNSDSSDIVQNEDETECLREPLRKASACSTYA
PETMMFLDKPILAPEPLVMDNLDSIMEQLNTWNFPIFDLVENIGRKCGRILSQVSYRLFE
DMGLFEAFKIPIREFMNYFHALEIGYRDIPYHNRIHATDVLHAVWYLTTQPIPGLSTVIN
DHGSTSDSDSDSGFTHGHMGYVFSKTYNVTDDKYGCLSGNIPALELMALYVAAAMHDYDH
PGRTNAFLVATSAPQAVLYNDRSVLENHHAAAAWNLFMSRPEYNFLINLDHVEFKHFRFL
VIEAILATDLKKHFDFVAKFNGKVNDDVGIDWTNENDRLLVCQMCIKLADINGPAKCKEL
HLQWTDGIVNEFYEQGDEEASLGLPISPFMDRSAPQLANLQESFISHIVGPLCNSYDSAG
LMPGKWVEDSDESGDTDDPEEEEEEAPAPNEEETCENNESPKKKTFKRRKIYCQITQHLL
QNHKMWKKVIEEEQRLAGIENQSLDQTPQSHSSEQIQAIKEEEEEKGKPRGEEIPTQKPD
Q
Function Cyclic nucleotide phosphodiesterase with a dual-specificity for the second messengers cAMP and cGMP, which are key regulators of many important physiological processes.
KEGG Pathway
Purine metabolism (hsa00230 )
cGMP-PKG signaling pathway (hsa04022 )
cAMP signaling pathway (hsa04024 )
Morphine addiction (hsa05032 )
Reactome Pathway
G alpha (s) signalling events (R-HSA-418555 )
cGMP effects (R-HSA-418457 )

Molecular Interaction Atlas (MIA) of This DTT

Molecular Interaction Atlas (MIA) Jump to Detail Molecular Interaction Atlas of This DTT
5 Approved Drug(s) Targeting This DTT
Drug Name Drug ID Indication ICD 11 Highest Status REF
Aminophylline DML2NIB Bronchial asthma CA23 Approved [2]
Anagrelide DMSQ8MD Thrombocythemia 3B63 Approved [1]
Cilostazol DMZMSCT Intermittent claudication BD40.00 Approved [3]
Enoximone DMQVZJD Congestive heart failure BD10 Approved [4]
VESNARINONE DMBKX3C Cardiac failure BD10-BD13 Approved [5]
------------------------------------------------------------------------------------
1 Clinical Trial Drug(s) Targeting This DTT
Drug Name Drug ID Indication ICD 11 Highest Status REF
BEMORADAN DMUL6GY Heart failure BD10-BD13 Phase 2 [6]
------------------------------------------------------------------------------------
5 Discontinued Drug(s) Targeting This DTT
Drug Name Drug ID Indication ICD 11 Highest Status REF
CI-930 DMADPQX N. A. N. A. Discontinued in Phase 2 [7]
EMD-53998 DMVS8IE Cardiovascular disease BA00-BE2Z Discontinued in Phase 1 [6]
BMY-20844 DMDPJ8M N. A. N. A. Terminated [8]
IMAZODAN DMWTFO3 N. A. N. A. Terminated [9]
LAS-31180 DMW2K1L Heart failure BD10-BD13 Terminated [10]
------------------------------------------------------------------------------------
26 Investigative Drug(s) Targeting This DTT
Drug Name Drug ID Indication ICD 11 Highest Status REF
1,3,9,9a-Tetrahydro-imidazo[4,5-b]quinolin-2-one DM7U31Q Discovery agent N.A. Investigative [11]
1,3-Dihydro-imidazo[4,5-b]quinolin-2-one DMB9XR5 Discovery agent N.A. Investigative [11]
1,3-Dihydro-naphtho[2,3-d]imidazol-2-one DM8CYOP Discovery agent N.A. Investigative [11]
1,5-Dihydro-imidazo[2,1-b]quinazolin-2-one DMYA25G Discovery agent N.A. Investigative [12]
2-Morpholin-4-yl-8-phenylethynyl-chromen-4-one DMNKHOI Discovery agent N.A. Investigative [13]
2-morpholino-7-(2-phenylethynyl)-4H-chromen-4-one DM4XKYN Discovery agent N.A. Investigative [13]
2-morpholino-7-phenyl-4H-chromen-4-one DMK7WON Discovery agent N.A. Investigative [13]
5-Methyl-1,3-dihydro-imidazo[4,5-b]quinolin-2-one DM0E1Y9 Discovery agent N.A. Investigative [11]
6-(2-Imidazol-1-yl-vinyl)-1H-quinolin-2-one DMXZWOA Discovery agent N.A. Investigative [9]
6-Imidazol-1-yl-3,4-dihydro-1H-quinolin-2-one DMRMSU5 Discovery agent N.A. Investigative [9]
6-Pyridin-3-yl-3,4-dihydro-1H-quinolin-2-one DMG5ABT Discovery agent N.A. Investigative [9]
7-Chloro-1,3-dihydro-imidazo[4,5-b]quinolin-2-one DMWUS5Q Discovery agent N.A. Investigative [11]
7-Ethoxy-1,3-dihydro-imidazo[4,5-b]quinolin-2-one DMI16MD Discovery agent N.A. Investigative [11]
7-Fluoro-1,3-dihydro-imidazo[4,5-b]quinolin-2-one DMNRCDI Discovery agent N.A. Investigative [11]
7-Iodo-1,5-dihydro-imidazo[2,1-b]quinazolin-2-one DM6K5NF Discovery agent N.A. Investigative [12]
7-Methyl-1,3-dihydro-imidazo[4,5-b]quinolin-2-one DM5EQJU Discovery agent N.A. Investigative [11]
8-Chloro-1,3-dihydro-imidazo[4,5-b]quinolin-2-one DM5IGOL Discovery agent N.A. Investigative [11]
8-Methyl-1,3-dihydro-imidazo[4,5-b]quinolin-2-one DM92XPO Discovery agent N.A. Investigative [11]
8-methyl-2-morpholino-7-phenoxy-4H-chromen-4-one DMWZ27A Discovery agent N.A. Investigative [13]
8-methyl-2-morpholino-7-phenyl-4H-chromen-4-one DMUI1YZ Discovery agent N.A. Investigative [13]
BENZOYLENUREA DMY5O1U Discovery agent N.A. Investigative [14]
isobutylmethylxanthine DM46F5X Discovery agent N.A. Investigative [3]
KURAIDIN DMLDUJ1 Discovery agent N.A. Investigative [15]
KURARINOL DMRV5YE Discovery agent N.A. Investigative [15]
SOPHOFLAVESCENOL DM8Y1S7 Discovery agent N.A. Investigative [15]
TETRAHYDROBENXIMIDAZOLE DMNURE0 Discovery agent N.A. Investigative [7]
------------------------------------------------------------------------------------
⏷ Show the Full List of 26 Investigative Drug(s)

Molecular Expression Atlas (MEA) of This DTT

Molecular Expression Atlas (MEA) Jump to Detail Molecular Expression Atlas of This DTT
Disease Name ICD 11 Studied Tissue p-value Fold-Change Z-score
Asthma CA23 Nasal and bronchial airway 8.06E-01 -0.04 -0.15
Thrombocythemia 3B64 Whole blood 3.33E-01 1.35E-02 0.14
Coronary artery disease BA80-BA8Z Peripheral blood 1.33E-01 -0.04 -0.38
Chronic obstructive pulmonary disease CA23 Lung tissue 1.18E-01 0.12 0.48
Chronic obstructive pulmonary disease CA23 Small airway epithelium 6.10E-01 -0.05 -0.16
------------------------------------------------------------------------------------

References

1 Hydroxyurea compared with anagrelide in high-risk essential thrombocythemia. N Engl J Med. 2005 Jul 7;353(1):33-45.
2 Topical fat reduction from the waist. Diabetes Obes Metab. 2007 May;9(3):300-3.
3 A new generation of phosphodiesterase inhibitors: multiple molecular forms of phosphodiesterase and the potential for drug selectivity. J Med Chem. 1985 May;28(5):537-45.
4 Inhibitors of cyclic AMP phosphodiesterase. 2. Structural variations of N-cyclohexyl-N-methyl-4-[(1,2,3,5-tetrahydro- 2-oxoimidazo[2,1-b]quinazolin... J Med Chem. 1987 Feb;30(2):303-18.
5 Design, synthesis and biological evaluation of 6-(benzyloxy)-4-methylquinolin-2(1H)-one derivatives as PDE3 inhibitors. Bioorg Med Chem. 2010 Jan 15;18(2):855-62.
6 Drugs@FDA. U.S. Food and Drug Administration. U.S. Department of Health & Human Services. 2015
7 Cardiotonic agents. 9. Synthesis and biological evaluation of a series of (E)-4,5-dihydro-6-[2-[4-(1H-imidazol-1-yl)phenyl]ethenyl]-3 (2H)-pyridazi... J Med Chem. 1989 Feb;32(2):342-50.
8 Inhibitors of blood platelet cAMP phosphodiesterase. 3. 1,3-Dihydro-2H-imidazo[4,5-b]quinolin-2-one derivatives with enhanced aqueous solubility. J Med Chem. 1992 Jul 10;35(14):2688-96.
9 3,4-Dihydroquinolin-2(1H)-ones as combined inhibitors of thromboxane A2 synthase and cAMP phosphodiesterase. J Med Chem. 1992 Feb 21;35(4):620-8.
10 Pharmacological profile of LAS 31180, a new inotropic/vasodilator quinolone derivative. Arzneimittelforschung. 2000 Nov;50(11):980-6.
11 1,3-Dihydro-2H-imidazo[4,5-b]quinolin-2-ones--inhibitors of blood platelet cAMP phosphodiesterase and induced aggregation. J Med Chem. 1991 Sep;34(9):2906-16.
12 Inhibitors of cyclic AMP phosphodiesterase. 3. Synthesis and biological evaluation of pyrido and imidazolyl analogues of 1,2,3,5-tetrahydro-2-oxoim... J Med Chem. 1988 Nov;31(11):2136-45.
13 Analysis of anti-PDE3 activity of 2-morpholinochromone derivatives reveals multiple mechanisms of anti-platelet activity. Bioorg Med Chem Lett. 2006 Feb 15;16(4):969-73.
14 CODES, a novel procedure for ligand-based virtual screening: PDE7 inhibitors as an application example. Eur J Med Chem. 2008 Jul;43(7):1349-59.
15 A prenylated flavonol, sophoflavescenol: a potent and selective inhibitor of cGMP phosphodiesterase 5. Bioorg Med Chem Lett. 2002 Sep 2;12(17):2313-6.